Dive Brief: Madrigal Pharmaceuticals said its pioneering medicine for a common liver disease brought in $137.3 million in the first quarter, surpassing analyst estimates by more than $20 million.  More than 17,000 patients have now taken the drug, known as …

Biogen Inc. BIIB reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52. The company reported sales of $2.43 billion, up 6% year over year on a …

Local cannabis compliance detectives flag flame, cloud, and maple leaf emojis when browsing social media platforms. Keeping up with coded references to cannabis was a crucial component of a six-week investigation that led the Santa Barbara County Sheriff’s …

(Reuters) - Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates, sending its shares down 4% in premarket trading. Separately, CVS Health …

(Reuters) - Eli Lilly on Thursday posted better-than-expected first quarter revenue and profit, although sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates, sending its shares down 2% in premarket trading. The …

ASX-listed Dimerix has landed one of the biggest licensing deals by an Australian biotechnology company after US pharmaceutical group Amicus Therapeutics agreed to $940 million in payments for future sales of its kidney disease drug. Shares in Melbourne- …

First Solar, Inc. FSLR shares are trading lower on Wednesday after the company reported worse-than-expected earnings for the first quarter and cut its full-year outlook. What To Know: First Solar reported first-quarter earnings per share of $1.95, missing …

On Wednesday, British multinational pharmaceutical GSK Plc GSK reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. Analysts had estimated sales of $7.46 billion. Vaccine sales fell …

… involvement in one or more drug sales that took place at the …

Gilead Sciences agreed to pay $202 million to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV medicines, the latest example of a controversial practice that has come back to haunt numerous drugmakers over …